BET Bromodomain Inhibitor ZEN-3694 trials for Breast cancer

All BET Bromodomain Inhibitor ZEN-3694 trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying BET Bromodomain Inhibitor ZEN-3694 for Breast cancer

• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
  NCT05111561 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
  NCT05372640 · Phase: Phase 1 · Ages: 12 Years and older · Sex: All (male and female) · 7 locations

Common questions

How many trials study BET Bromodomain Inhibitor ZEN-3694 for Breast cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.